Tau expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy

Kun Wang(Union Hospital), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Yan‐Hui Liu(Hainan University), Fangping Xu(Guangdong Academy of Medical Sciences), Xuerui Li(Guangdong General Hospital), Jian Zu(Xi'an University of Architecture and Technology), Quantong Deng(Guangdong General Hospital), Ning Liao(Guangdong General Hospital)
Tumor Biology
September 13, 2012
10.1007/s13277-012-0507-z
Cited by 40

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k